Patent ID: 8741884

Claim:
A compound of formula I where R 1 is alkyl, hydroxyalkyl, alkoxyalkyl, haloalkyl, cycloalkyl, hydroxycycloalkyl, alkoxycycloalkyl, halocycloalkyl, cycloalkenyl, benzyl, indanyl, or alkylcarbonyl; R 2 is hydrogen, halo, cyano, alkyl, haloalkyl, alkoxy, haloalkoxy, CO 2 R 6 , or CON(R 7 )(R 8 ); R 3 is hydrogen, alkyl, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, or dialkyaminocarbonyl; R 4 is hydrogen or alkyl; R 5 is hydrogen, alkyl, (amino)alkyl, (alkylamino)alkyl, or (dialkylamino)alkyl; R 6 is hydrogen, alkyl, or benzyl; R 7 is hydrogen, alkyl, pyrrolidinonyl, piperidinonyl, homopiperazinonyl, (R 9 )alkyl, (Q)alkyl, ((R 9 )alkyl)-Q-alkyl, (R 9 )(R 9 )alkyl, or (R 9 )(Q)alkyl; or R 7 is pyrrolidinonyl, piperidinonyl, homopiperazinonyl, or R 8 is hydrogen or alkyl; or R 7 and R 8 taken together with the nitrogen to which they are attached is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl, and is substituted with 0-2 substituents selected from alkyl, (CO 2 R 6 )alkyl, CO 2 R 6 ,CON(R 10 )(R 10 ), and N(R 10 )CO 2 R 6 ; or R 7 and R 8 taken together with the nitrogen to which they are attached is a spiro [3-7.3-7] bicyclic ring system where the bicylic ring system contains 0-1 additional nitrogens, and is substituted with 0-2 substituents selected from alkyl, (CO 2 R 6 )alkyl, CO 2 R 6 , CON(R 10 )(R 11 ), and N(R 10 )CO 2 R 6 ; R 9 is CO 2 R 6 , C(O)(N(R 10 )(R11)), C(═NR 12 )(N(R 10 )(R 11 )),CON(R 10 )SO 2 R 13 ,N(R 10 )(R 11 ), N(R 10 )COR 6 ,N(R 10 )COPh, N(R 10 )CO 2 R 6 ,N(R 10 )C(O)(N(R 10 )(R 11 )),N(R 10 )C(═NR 12 )(N(R 10 )(R 11 )), or (R 13 )SO 2 ; R 10 is hydrogen or alkyl; R 11 is hydrogen or alkyl; or N(R 10 )(R 11 ) taken together with the nitrogen to which they are attached is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl R 12 is hydrogen, alkyl, or phenyl; R 13 is alkyl, cycloalkyl, or phenyl; Q is cycloalkyl, phenyl, tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl, and is substituted with 0-2 R 9 substituents; X is an alkylene or alkenylene chain containing 0-6 groups selected from the group consisting of O, NR 3 , S, S(O), S(O 2 ), C(O)O, C(O)NR 4 , OC(O)NR 4 , NR 4 C(O)NR 4 , NR 4 C(NR 12 )NR 4, , and Z, provided that O, NR 3 , S, S(O), S(O 2 ), C(O)O, C(O)NR 4 , OC(O)NR 4 , NR 4 C(O)NR 4 , and NR 4 C(NR 12 )NR 4 do not directly bond to each other or to NH, such that ring A is 13-24 membered; and where the alkylene or alkenylene chain is substituted with 0-6 substituents selected from the group consisting of alkyl, alkylidinyl, hydroxy, alkoxy, and phenyl where the phenyl substituent is further substituted with 0-4 cyano, halo, alkyl, haloalkyl, alkoxy, or haloalkoxy substituents; Y is CH 2 , O, CO 2 , or C(O)NR 5 ; and Z is C 3-7 cycloalkylene or phenylene; or a pharmaceutically acceptable salt therof.